SearchBox:

Search Term: " old; "

  Messages 1-6 from 6 matching the search criteria.
Kaneka QH - Ubiquinol Darrell Miller 11/30/07
Acai - Super Antioxidant from Brazil Darrell Miller 7/27/07
Natural Coenzyme Q10 (Ubiquinone) Darrell Miller 7/27/07
Detox with ParaPhyte from Source Naturals Darrell Miller 4/16/07
EpiCore Benefits Darrell Miller 4/9/07
Glycerylphosphorylcholine -- Supports Cognitive Function in AD ... Darrell Miller 5/24/05




Kaneka QH - Ubiquinol
TopPreviousNext

Date: November 30, 2007 03:40 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: Kaneka QH - Ubiquinol

UBIQUINOL COQH

CoQ10 with Heightened Absorption

 

• New, active form of CoQ10 with heightened absorption, which results in increased blood serum levels

• Provides powerful antioxidant support by blocking free radical damage within cell membranes.

• Supports cardiovascular health and energy production by aiding the synthesis of mitochondrial ATP.

• Supports normal, healthy liver functioning by reducing oxidative stress.

 

Source Naturals Offers a New, Premier CoQ10 Product

 

UBIQUINOL COQH bundles all the great benefits of the powerful antioxidant CoQ10 into a superior form that enhances absorption into the body and increases blood serum levels. UBIQUINOL COQH facilitates the production of cellular energy in the mitochondria, which in turn provides robust support to some of the body’s most demanding systems. Both the cardiovascular and liver systems rely heavily on CoQ10 to help generate the energy needed for healthy functioning. Also found in high levels within cellular membranes, CoQ10 works as an effective antioxidant that protects the integrity of mitochondrial and lipid membranes.

 

1 softgel contains:

 

Kaneka QH™ Ubiquinol 100 mg


UBIQUINOL COQH

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=1642)


Acai - Super Antioxidant from Brazil
TopPreviousNext

Date: July 27, 2007 02:33 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: Acai - Super Antioxidant from Brazil

Acaí Extract

Super Antioxidant from Brazil

• Powerful concentration of natural antioxidants that benefit every cell of the body

• Natural, effective free radical scavengers

• Rich in polyphenols and anthocyanins

• As seen on national media

Acaí is a palm from the Amazonian rainforest. It has small, purple fruits that have been used by Brazilian natives for food and health for hundreds of years. The active constituents in Acaí are polyphenols and anthocyanins. Scientific studies have shown these compounds to be powerful antioxidants, benefiting the entire body by protecting the cells from free radicals.

2 capsules contain:

Vitamin C (naturally occurring) 8 mg

Acaí Fruit Extract (4:1) 1 g

Suggested Use: 2 capsules daily.



--
Buy Acai at Vitanet

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=1587)


Natural Coenzyme Q10 (Ubiquinone)
TopPreviousNext

Date: July 27, 2007 02:08 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: Natural Coenzyme Q10 (Ubiquinone)

CoQ-Quick™

Natural Coenzyme Q10 100 mg

• Supports cardiovascular function.

• Vital for the production of ATP, the energy molecule.

• Potent antioxidant.

Addresses six of the twelve SystemiCareTM deep metabolic systems identified by Source

Naturals as critical for optimum health: Energy Production, Circulation/Heart Health, Liver/

Detox, Immunity, Cognition/Nerves, and Antioxidant Defense.

Delicious, natural orange flavor.

One tablet contains:

 

Coenzyme Q10 (ubiquinone) 100 mg

 

Suggested Use: 1 tablet daily with a meal. Not a sublingual tablet. Place tablet on top of tongue and allow tablet to dissolve while lightly pressing tongue against the roof of the mouth. Tablet will disintegrate rapidly. Swallow CoQ-Quick contents after the tablet has disintegrated.



--
Vitanet ®

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=1586)


Detox with ParaPhyte from Source Naturals
TopPreviousNext

Date: April 16, 2007 04:10 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: Detox with ParaPhyte from Source Naturals

ParaPhyteIntestinal Detoxifier

 

• Clears and detoxifies the GI tract

• Promotes a healthy immune system

• Aids the development of natural, healthy gastrointestinal flora ParaPhytecontains potent, traditional herbal ingredients that support and defend the body’s healthy gastrointestinal flora. Additional herbal ingredients soothe the gastrointestinal tract and maintain digestive balance.

 

2 tablets contain:

Black Walnut Hull Extract (4:1)...................... 375 mg Artichoke Leaf Extract......................100 mg

MSM (methylsulfonylmethane [OptiMSM]....300 mg (2.5% cynarins)

Garlic Clove..................................................... 250 mg Pau D’Arco Bark................................100 mg

Butternut Bark Extract (4:1)........................... 250 mg Slippery Elm Bark.............................100 mg

Grapefruit Seed Extract (Citricidex)............. 150 mg Quassia Wood Extract (4:1)................50 mg

(49% polyphenolic compounds) Fennel Seed.........................................50 mg

Sweet Wormwood Aerial Parts Extract (8:1) 125 mg Gentian Root Extract (5:1)..................25 mg

Clove Fruit....................................................... 100 mg Marshmallow Root Extract (4:1)........25 mg

 

Suggested Use: 1 to 2 tablets, twice daily between meals with 8 ounces of water. Fasting or eating lightly is recommended during the first day or two. During this time it is important to drink plenty of fluids and juices to maintain electrolyte balance and hydration.

To Order Call 1-800



--
Detox your intestinal tract with vitamins from Vitanet Health Foods

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=1512)


EpiCore Benefits
TopPreviousNext

Date: April 09, 2007 05:02 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: EpiCore Benefits

Benefits

EpiCor® is a unique and novel dietary supplement used for support of immune health, with a fascinating history of discovery. In 1943, a company in Cedar Rapids, Iowa called Diamond V Mills, Inc. began manufacturing and selling a fermentation product from the yeast Saccharomyces cerevisiae, the same yeast used in bread and beer making. The product was and still is used as an additive for animal feed to help improve digestion as well as overall health in animals. It has been on the market for over 60 years.

Interestingly, when the company became self-insured, they became aware of unusually low rates of illness in employees that worked in the manufacturing plant for this animal product. This led to very low increases in their insurance premiums over the years compared to other companies, saving them quite a lot of money. Hence they began to investigate what might be the cause of the “healthfulness” of the employees at the fermentation plant. This investigation and subsequent research studies led to the formation of a new company called Embria Health Sciences, which now produces EpiCor® as a supplement for humans to support immune system health.1 Doctor’s Best® is proud to now offer the benefits of EpiCor® to its customers.

Beneficial Support of the Immune System and Activation of Natural Killer (NK) Cells in vitro*

A comparison study was performed on blood from 10 fermentation plant workers compared to that from 10 age and gender matched controls. The fermentation plant workers had several immune cell parameters that appeared superior to the control group. These included decreased levels of CD8 cells resulting in significantly increased CD4 to CD8 ratios, significantly improved cytotoxic natural killer (NK) cell activity even though total NK cells were decreased in number, higher killing efficiency of NK cells, significantly increased levels of secretory IgA, increased numbers of EpiCor™ specific antibodies, higher levels of red blood cell intracellular glutathione, and significantly lower levels of immune complexes. These results represent benefits on various cellular players of both the specific and innate parts of the immune system.1,3,4

NK cells are one of the first lines of defense used by the immune system. An in vitro study performed on human cells showed that NK cells were activated after incubation with EpiCor®, as evaluated by expression of the CD69 activation marker. The CD25 marker (IL-2 receptor) was also induced in the NK cells, although to a lesser degree.1,2 B cell activation was also noted through increased expression of CD80 and CD86 markers.2 Immediate increases in calcium levels were evident in peripheral blood mononuclear cells after exposure to EpiCor®, suggesting increased activation through calcium regulation.2

High Metabolite Immunogen*: Nutrient Make-up

Production of EpiCor® utilizes the common and harmless bakers or brewers yeast Saccharomyces cerevisiae in a patented process called MetaGen4™, a multi-stage fermentation and drying process. It differs from other yeast products in that it contains both the yeast itself as well as the metabolites or “nutrilites” formed by the fermentation process, which are present in the media.1 Together the media containing the metabolites and the yeast are dried to form EpiCor®. Analysis of EpiCor® reveals that it contains a mixture of natural polyphenols, phytosterols, beta-glucans, mannan oligosaccharides, fiber, trace amounts of B vitamins and minerals, as well as a host of other nutritional compounds.1,2

Beneficial Antioxidant Activity*

EpiCor® was tested for antioxidant activity in an in vitro assay called the Oxygen Radical Absorbance Capacity assay (ORAC). In this assay, EpiCor® was shown to have a total ORAC antioxidant level of 610 micromol TE (tocopherol (vitamin E) equivalents) units (ORAC units) per gram dry weight, which soared above other high antioxidant level foods such as cranberries (93 ORAC units per gram dry weight) and blueberries (62 ORAC units per gram dry weight).1,3,5

In another study, freshly isolated human neutrophils were treated with EpiCor® followed by the free radical generator hydrogen peroxide. Cells were treated with a dye that fluoresces when attacked by free radicals. Those cells treated with EpiCor® showed decreased fluorescence intensity compared to control cells not treated with EpiCor®, verifying antioxidant activity in vitro.2

Safety

Numerous safety tests have been conducted on EpiCor®, revealing an extremely safe profile. Animal studies performed by a leading toxicology laboratory showed no indication of any toxic effects of EpiCor®. An acute oral toxicity study on 20 rats showed that the product was safe when given to rats at a single oral dose of 2000 milligrams per kilogram of body weight (equivalent to a human ingesting 280 capsules at once). After 2 weeks the rats showed no clinical symptoms, no deaths, no abnormalities in body weight, and no gross pathological changes. The same safety results were found in a subchronic toxicity study where rats were given up to 1500 milligrams daily for 90 days (equivalent to a human ingesting up to 210 capsules daily for 1.5 years). Again, absolutely no signs or symptoms of toxicity were noted in these animals.1,3

In addition, a standard bacterial reverse mutagenicity test (AMES test) as well as a mammalian cell mutation assay using mouse lymphoma cells revealed no evidence of any increase in mutation rates after exposure to EpiCor®. EpiCor® also showed no evidence of mitogenicity (inducing increased cell division) in a human lymphocyte proliferation assay. This suggests that EpiCor® does not cause over-reactivity of cells1,3.

The effect of EpiCor® on specific liver enzymes CYP1A2 and CYP3A4 (enzymes involved in metabolizing certain drugs and other compounds) was assessed. Immortalized hepatocytes (liver cells) were treated with various concentrations of EpiCor® and compared to both positive and negative controls. EpiCor® did not increase the expression or activity of the liver enzymes, suggesting that it may not affect the metabolism of other substances or medications metabolized by these enzymes if they are taken simultaneously. It also did not appear to be toxic to the cells as measured by lactate dehydrogenase assays and microscopic analysis.1

Lastly, EpiCor® was tested for safety in humans in an open label study on 15 adult men and women given a single 500 milligram dose for 30 days. On various days throughout the study vital signs were monitored, and blood and urine samples were analyzed. No clinically relevant abnormal effects on the participants were found1.

 

EpiCor® also currently has received self-affirmed Generally Regarded as Safe (GRAS) status by an expert panel that included eminent toxicologists1.

 

EpiCor® is a novel compound with an incredibly unique composition that has been shown to enhance immune system function.*

Suggested Adult Use: Take one capsule daily with or without food.

 

 

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 

Scientific References

1. Embria Health Sciences

2. Hart et al. A new Saccharomyces cerevisiae based product has anti-inflammatory effects while specifically activating human NK and B lymphocyte subsets. Unpublished study, personal communication.

3. Schauss AG, Jensen G, Vojdani A, Financsek I. After decades of ingestion by farm animals, the discovery of a yeast fermentate with unexpected significant immune modulatory activity when consumed by humans. [abstract] Journal of the American College of Nutrition, 2006; 25(5): 465.

4. Schauss AG, Vodjani A. Discovery of an edible fermentation product with unusual immune enhancing properties in humans. [abstract] FASEB J, 2006; 20(4):A143.

5. Wu X, Beecher GR, Holden JM, Haytowitz DB, Gebhardt SE, Prior RL. Lipophilic and hydrophilic antioxidant capacities of common foods in the United States. J Agric Food Chem 2004 Jun 16;52(12):4026-3



--
Buy EpiCore 500mg at Vitanet

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=1508)


Glycerylphosphorylcholine -- Supports Cognitive Function in AD ...
TopPreviousNext

Date: May 24, 2005 09:52 AM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: Glycerylphosphorylcholine -- Supports Cognitive Function in AD ...

Cognitive Improvement in Mild to Moderate Alzheimer's Dementia After Treatment with the Acetylcholine Precursor Choline Alfoscerate: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Maria De Jesus Moreno Moreno, MD Instituto Nacional de la Senectud, Mexico City, Mexico


This study assessed the efficacy and tolerability of the cholinergic precursor choline alfoscerate (CA) in the treatment of cognitive impairment due to mild to moderate AD (Alzheimer's disease).

in both men and woman they consistently improved after 90 and 180 days versus baseline with adiministration of GPC three times a day, whereas in the placebo group they remained unchanged or worsened. Statistically significant differences were observed between treatments after 90 and 180 days.

Keypoints:

  • improved cognition and global function
  • showed a statistically significant improvement after 90 and 180 days of treatment
  • Increased neurotransmission
  • With out treatment men and woman declined consistantly
  • references:

    Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction, Science. 1982;217:408-414. 2. Larson EB, Kukull WA, Katzman RL. Cognitive impairment: Dementia and Alzheimer's disease. Annu Rev Public Health. 1992;13:431-449. 3. Hofman A, Rocca WA, Brayne C, et al, for the European Prevalence Research Group. The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings. Int d Epidemiol. 1991;20:736-748. 4. Blackwood W, Corsellis JAN, eds. Greenfield's Neuropathology. 3rd ed. London: Arnold; 1976. 5. Geldmacher DS. Cost-effective recognition and diagnosis of dementia. 5emin Neurol. 2002;22:63-70. 6. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2:1457-1459. 7. Perry EK. The cholinergic hypothesis--ten years on. Br Med Bull. 1986;42:63-69. 8. Giacobini E. From molecular structure to Alzheimer therapy. Jpn d Pharmacol. 1997;74:225-241. 9. Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications. Neurochem Int. 1998;32:413-419. 10. Brinkman SD, Smith RC, Meyer JS, et al. Lecithin and memory training in suspected Alzheimer's disease. J Gerontol. 1982;37:4-9. 11. Davis E, Emmerling MR, Jaen JC, et al. Therapeutic intervention in dementia. Crit Rev Neurobiol. 1993;7:41-83. 12. Amenta E Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropiate approaches? Mech Ageing Dev. 2001;122:2025-2040. 13. Sigala S, Imperato A, Rizzonelli P, et al. k-Alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eurd Pharmacol. 1992;211:351-358. 14. Govoni S, Battaini E Lucchi L, et al. Effects of alpha-glycerylphosphorylcholine in counteracting drug-induced amnesia: Through cholinergic and non-cholinergic mechanisms [in Italian]. Basi Raz Ter. 1991;21:75-78. 15. Canonico PL, Nicoletti F, Scapagnini U. Neurochemical and behavioral effects of alpha-glycerylphosphorylcholine [in Italian]. Basi Raz Te~ 1990;20: 53-54. 191 CLINICAL THERAPEUTICS ® 16. Parnetti L, Amenta E Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: An analysis of published clinical data. Mech Ageing Dev. 2001;122:2041-2055. 17. Venn RD. The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general-purpose psychogeriatric rating scale. Gerontology. 1983;29:185-198. 18. Di Perri R, Coppola G, Ambrosio LA, et al. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Int Med Res. 1991;19:330-341. 19. Frattola L, Piolti R, Bassi S, et al. Multicenter clinical comparison of the effects of choline alphoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. Curt Ther Res Clin Exp. 1991;49:683-693. 20. Muratorio A, Bonuccelli U, Nuti A, et al. A neurotropic approach to the treatment of multi-infarct dementia using L-c~-glycerylphosphorylcholine. Curt Ther Res Clin Exp. 1992;52:741-75l. 21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: APA; 1994. 22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944. 23. Folstein ME Folstein SE. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198. 24. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke. 1983;14:399-401. 25. Hamilton M. A rating scale for depression.J Neurol Neurosurg Psychiatry. 1960;23:56-62. 26. Hamilton M. Development of a rating scale for primary depressive illness. BrJ Soc Clin Psych& 1967;6:278-296. 27. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. AmJ Psychiatry. 1984;141:1356-1364. 28. Reisberg B, Ferris SH, De Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136-1139. 29. National Institute of Mental Health. Clinical global impressions. In: Guy W, ed. ECDEU Assessment for Psychopharmacology. Revised edition. Rockville, Md: National Institute of Mental Health; 1976:217-222. 30. Burns A, Russell E, Page S. New drugs for Alzheimer's disease. Br J Psychiatry. 1999;174:476-479. 31. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7:159-169. 32. Knapp MJ, Knopman DS, Solomon PR, et al, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991. 192 M. Moreno 33. Lindstrom MJ, Bates DM. Newton-Rapshon algorithms for linear-mixed effects models for repeated measure data. J Am Stat Assoc. 1998;83:1014-1022. 34. Thai LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-711. 35. Rogers SL, Friedhoff LT, for the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303. 36. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, for the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998; 158:1021-1031. 37. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and the safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65. 38. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999;318: 633-638. 39. Amenta E Bronzetti E, Del Valle M, Vega JA. Effects of alpha-glycerylphosphorylcholine in neuroanatomy of aging brain in experimental animals [in Italian]. Basi Raz Te~: 1990;20:31-38. Address correspondence to: Scientific Department, Italfarmaco SpA, via dei Lavoratori 54, 20092 Cinisello Balsamo, Milan, Italy.

    (https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=98)



  • VitaNet ® LLC. Discount Vitamin Store.